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 32 
Assessment of Breathlessness in Lung Cancer: Psychometric Properties of 33 
the Dyspnoea-12 Questionnaire 34 
Abstract 35 
Content: The Dyspnoea-12 (D-12) is a well validated instrument in respiratory illnesses for 36 
breathlessness assessment, but its psychometric properties have not been tested in lung cancer. 37 
Objectives: To demonstrate the psychometric properties of the D-12 in lung cancer patients. 38 
Methods: Baseline data from a lung cancer feasibility trial were adopted for this analysis. D-12 and a 39 
series of patient-reported tools including five Numeric Rating Scales (NRS), the Hospital Anxiety and 40 
Depression Scale (HADS) and the Lung Cancer Symptom Scale (LCSS) were employed for the 41 
psychometric assessment. Spearman’s correlation coefficients (rs) were used to estimate the 42 
convergent validity of the D-12 with the NRS, HADS and LCSS. Exploratory factor analysis was 43 
performed to examine construct validity. Reliability was tested by Cronbach’s alpha and item-to-total 44 
correlations. D-12 score difference between patients with or without anxiety, depression and COPD 45 
was explored to identify its discriminate performance. 46 
Results: One hundred and one lung cancer patients were included. There were significantly positive 47 
correlations between the D-12 and the HADS, LCSS, and NRS scales measuring the breathlessness 48 
severity and its associated affective distress. Factor analysis clearly identified two components 49 
(physical and emotional) of the D-12. Cronbach’s alpha for D-12 total, physical and emotional 50 
subscales was 0.95, 0.92 and 0.94, respectively. Patients with anxiety or depression demonstrated 51 
significantly higher D-12 scores than those without it, and patients with COPD reported significantly 52 
more severe breathlessness than those without COPD. 53 
Conclusion: The D-12 is a valid and reliable self-reported questionnaire for use in breathlessness 54 
assessment in lung cancer patients. 55 
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Introduction 63 
Breathlessness is defined as “a subjective experience of breathing discomfort that consists of 64 
qualitatively distinct sensations that vary in intensity” [1]. It is one of the most distressing symptoms 65 
frequently identified in lung cancer [2-5]. Evidence supports breathlessness as a multidimensional 66 
experience, as the presence of breathlessness is associated with physical and emotional distress such 67 
as fatigue, anxiety, depression, and deterioration of quality of life (QoL) [2, 5, 6]. As breathlessness is 68 
a subjective symptom involving both physical and psychological factors, its measurement should 69 
be multidimensional using patient-reported approaches that encompass its different dimensions [1, 70 
7]. 71 
There is a plethora of instruments for assessing breathlessness, although most of them have been 72 
validated for chronic obstructive pulmonary disease (COPD) [8]. Commonest used unidimensional 73 
tools for breathlessness assessment include the modified Borg scale, visual analogue scale (VAS) and 74 
numerical rating scale (NRS) [8, 9]. Although these tools are easy to complete, the use of different 75 
endpoints makes it difficult to do comparisons between studies [8], and their unidimensional nature 76 
requires the use of multiple instruments to obtain a full understanding of breathlessness. The 77 
Medical Research Council (MRC) dyspnoea scale is also a popular tool for grading breathlessness 78 
[8]. However, it is only activity-specific and it is weak in its association with patients’ physiological 79 
and functional distress, which make it impossible to use for the multidimensional assessment of 80 
breathlessness [8, 10]. 81 
Multidimensional instruments for breathlessness assessment have been introduced, such as the 82 
Cancer Dyspnoea Scale (CDS) [11-13]. But the CDS only includes the anxiety as patients’ 83 
psychological distress and the evidence in terms of its responsiveness and minimal clinically 84 
important difference (MCID) is lacking [11-14]. The Chronic Respiratory Questionnaire (CRQ) is a 85 
good candidate for breathlessness assessment [14]. It has been well validated in chronic respiratory 86 
diseases such as COPD and interstitial lung disease (ILD) [14], and the psychometric properties of its 87 
short form have also been preliminarily identified in lung cancer [15]. However, the patient may 88 
take a relatively long time to complete the entire CRQ, and small changes in breathlessness may not 89 
be captured by repeated administration of the CRQ [16, 17]. Another tool named Breathlessness 90 
Assessment Guide has also been developed for lung cancer without any psychometric testing [18, 91 
19]. There is a shortage of instruments that could be used for measuring breathlessness among 92 
different advanced diseases [8]. 93 
The Dyspnoea-12 (D-12) is a convenient patient-reported scale for measuring the severity of 94 
breathlessness [20]. Breathlessness is quantified by using 12 descriptors to cover both its 95 
physical and psychological dimensions [20]. The D-12 has established its validity and reliability in 96 
COPD [20], asthma [21], ILD [22] and pulmonary hypertension [23], but its psychometric properties 97 
have not yet been assessed in lung cancer. Therefore, the aim of this study was to determine the 98 
validity and reliability of the D-12 in lung cancer, by using data from a recent lung cancer feasibility 99 
randomised controlled trial (RCT) [24]. 100 
Materials and Methods 101 
Research ethical approval was granted to this study, and research governance approval was also 102 
received from the study hospitals. All participants provided written informed consent. 103 
Overview of the Feasibility Trial 104 
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This was a multi-centre feasibility RCT conducted in the UK [24]. It aimed to feasibility test a non-105 
pharmacological intervention for managing the lung cancer respiratory distress symptom cluster 106 
(breathlessness-cough-fatigue). The intervention consisted of a couple of self-management 107 
approaches such as the techniques for breathing control, cough easing and self-acupressure [24]. A 108 
total of 107 lung cancer patients joined the study and 101 were included in the analysis. Participants 109 
completed self-reported outcome measures including a range of scales to assess symptoms, 110 
psychological distress and QoL [24]. In the current study, only baseline data were used for analysis. 111 
Study Instruments 112 
The most pertinent outcome measures for examining the D-12 psychometric properties were 113 
included in this analysis. 114 
-Dyspnoea-12 Questionnaire (D-12) 115 
The D-12 uses 12 items to generate a global assessment of the severity of breathlessness [20]. 116 
Each item is rated on a 4-point Likert scale from 0 (none) to 3 (severe), and the total scores range 117 
from 0 to 36 with a higher score indicating more severe dyspnoea [21-23]. Items 1 to 7 are 118 
summed up to create the physical component score, and items 8 to 12 are used for calculating the 119 
emotional component score [21, 23]. MCID of the D-12 has been determined in the feasibility trial 120 
using anchor-based and distribution-based methods, with a value of 3 units [24]. 121 
-NRS Breathlessness Scales 122 
Five 0-10-point NRS scales were adopted to measure the average and worst breathlessness 123 
experienced during the past 24 hours (higher scores=worse conditions), breathlessness-related 124 
unpleasantness and distress (higher scores=worse conditions), and patients’ ability to cope with 125 
breathlessness (higher scores=better conditions) [24-26]. The NRS scales were used to explore the 126 
associations with the D-12 total and component scores. 127 
-Hospital Anxiety and Depression Scale (HADS) 128 
The HADS is a 14-item self-reported instrument for determining the general state of psychological 129 
distress, with seven items each assessing anxiety and depression respectively [27, 28]. Each item is 130 
rated from 0 to 3, thus the scores for either anxiety or depression scale range from 0 to 21 (higher 131 
scores=more severe outcomes) [27, 28]. For particular statistical purpose, a HADS anxiety score 132 
(HADS-A) of 8.0 or above was suggested as the presence of anxiety while a HADS depression score 133 
(HADS-D) of 8.0 or above was indicated as the presence of depression [28, 29]. The HADS was 134 
employed to explore the association with the D-12 as they both contain an emotional content for 135 
measuring psychological distress. 136 
-Lung Cancer Symptom Scale (LCSS) 137 
The LCSS is a QoL assessment tool with well documented psychometric properties [30, 31]. The LCSS 138 
patient-reported scale consists of nine items with six assessing prominent symptoms related to lung 139 
cancer and another three evaluating patients’ “symptomatic distress”, “activity status” and “overall 140 
QoL” [30]. All items use the 0-100 VAS scale (higher scores=worse outcomes) and the total score is 141 
computed as the mean of all the nine items [32]. The LCSS was used to explore its correlations with 142 
the D-12 as QoL in lung cancer has been proved to be negatively associated with dyspnoea [5]. 143 
Psychometric Assessment 144 
-Reliability and Validity 145 
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Internal consistency reliability for the D-12 was examined and the item-to-total correlations were 146 
adopted to explore the relationships between one single D-12 item score and the total D-12 score 147 
without that item [33]. Validity was examined by convergent validity and construct validity. 148 
Convergent validity is estimated by examining “whether the measured variables correlate with other 149 
measures of the same concept” [34]. Associations between the D-12 and the NRS, HADS and LCSS 150 
were explored to identify the D-12 convergent validity. Exploratory factor analysis (EFA) was 151 
applied to estimate the D-12 construct validity. 152 
-Acceptability, Floor and Ceiling Effects, Invariance and Discriminate Performance 153 
Acceptability of the D-12 was estimated by calculating the percentage of missing value across all the 154 
D-12 items. Percentages of the subjects who had the lowest and highest possible D-12 total score 155 
were computed respectively to estimate the floor and ceiling effects of the D-12. Invariance of the D-156 
12 was tested for age and gender factors. Discriminate performance analyses were considered for 157 
subjects with or without anxiety, depression and COPD. 158 
Statistical Analysis 159 
The IBM SPSS Statistics for Windows version 22.0 (IBM Corp, Armonk, NY, USA) was adopted for 160 
data analysis with the statistical significance setting as P˂0.05. Descriptive statistics were presented 161 
to summarise patients’ demographic data, acceptability, and the floor and ceiling effects of the D-12. 162 
Spearman’s correlation coefficients (rs) were adopted for exploring the associations between the D-163 
12 and the NRS, HADS and LCSS, as most of the instrument scores in our sample violated the 164 
assumption of normal distribution. Principal component analysis (PCA) with a varimax rotation 165 
(eigenvalues ˃1) was used for the EFA. Items that loaded ˃0.6 were retrieved for a potential factor. 166 
Independent-samples t-test or Mann-Whitney U test (as determined by the normality test) was 167 
adopted to estimate the D-12 score difference in different subgroups (e.g. anxious vs. not anxious, 168 
and COPD vs. non-COPD). Age difference was analysed by exploring the association (rs) between the 169 
D-12 and patients’ age. Internal consistency was estimated by Cronbach’s alpha, and an alpha score 170 
of 0.8 or above is determined as very good for an instrument [35]. An item-to-total correlation is 171 
viewed as adequate once the value reaches 0.4 [36]. 172 
Results 173 
Patients’ Demographic and Clinical Data 174 
One hundred and one participants were included. The majority of the patients were aged over 60 175 
years old and had dyspnoea. Around one third of them presented anxiety or depression (Table 1).  176 
D-12 Descriptive Analysis 177 
The mean score for D-12 total was 17.8 (SD=9.4), and it was 11.0 (SD=5.3) and 6.6 (SD=4.8) for D-12 178 
physical and D-12 emotional subscale, respectively (Figure 1). Missing values within the D-12 were 179 
identified in no more than four subjects for each item across items 1 to 8. No missing data were 180 
detected for items 9 to 12. Proportions of the patients with the lowest (0) and possibly highest score 181 
(as of 35 in this sample) of the D-12 total were 4.0% (4/101) and 1.0% (1/101), respectively.  182 
D-12 Convergent Validity 183 
D-12 scores were strongly and positively correlated with HADS and LCSS scores (all at P˂0.001). The 184 
highest rs was identified between D-12 emotional subscale and HADS anxiety subscale (rs=0.71, 185 
P˂0.001). Significantly positive correlations can be found between D-12 and NRS “average” and 186 
“worst” breathlessness, and “distress” and “unpleasantness” associated with breathlessness (rs 187 
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ranged from 0.48 to 0.64, all at P˂0.001). Slightly negative (but insignificant) correlations were 188 
shown between D-12 and NRS “ability to cope with breathlessness” (P˃0.05) (Table 2). 189 
D-12 Construct Validity 190 
There were two well-defined factors with items 1 to 7 clustering around the first factor (coefficients 191 
ranged from 0.68 to 0.81, representing the physical dimension of breathlessness) and items 8 to 12 192 
gathering around the second factor (coefficients ranged from 0.78 to 0.87, indicating the emotional 193 
dimension of breathlessness) (Table 3). 194 
D-12 Reliability 195 
Internal consistency of the entire D-12 questionnaire was already reported in the feasibility study 196 
paper, with the Cronbach’s alpha of 0.95 [24]. Internal consistency for the D-12 physical and 197 
emotional subscales was also excellent, with Cronbach’s alpha being 0.92 and 0.94, respectively. 198 
Adequate item-to-total correlations of the D-12 were identified, with the coefficients ranging from 199 
0.59 to 0.84 (mean 0.8). 200 
D-12 Invariance and Discriminate Performance 201 
There was no difference in D-12 scores between male and female patients (all at P˃0.05), and 202 
Spearman’s correlation also showed no association between D-12 and age (rs ranged from -0.15 to -203 
0.12, all at P˃0.05). Patients with anxiety or depression presented significantly higher D-12 scores 204 
than those without anxiety or depression (all at P˂0.001) (Table 4). Similarly, patients with COPD 205 
also had significantly higher D-12 scores than non-COPD patients (all at P˂0.05, Table 5). 206 
Discussion 207 
The D-12 is a short scale confirming earlier reports in non-cancer populations that has minimal 208 
missing data [23]. Acceptability of the D-12 was documented, as missing values across items and the 209 
floor and ceiling effects were minimal in the lung cancer sample. Given the good completion rate of 210 
the D-12 and its ability to gain an overall score that incorporates multidimensional aspects of 211 
dyspnoea severity, the clinical utility of the D-12 seems promising. 212 
Convergent validity of the D-12 was adequate. The significantly positive associations between the 213 
D-12 and the NRS scales indicated the possibility of using one single instrument instead of multiple 214 
tools to measure the overall severity of breathlessness. There was a negative (but insignificant) 215 
correlation between the D-12 and patients’ coping ability, which indicted that severe dyspnoea 216 
might impair the patients’ ability to cope with the symptom. However, it is also suggested that the 217 
distress induced by the symptoms emotional component might, in turn, motivate patients’ behaviour 218 
[21]. The potentially bidirectional function of psychological distress might partially contribute to the 219 
above insignificant correlation. As coping ability is a complex construct which is almost impossible to 220 
capture in a single item scale, its relationship with dyspnoea is worthy of further exploration. 221 
The D-12 was strongly correlated with anxiety and depression, as both the HADS and D-12 possess 222 
the psychological construct that measures patients’ emotional status. Theoretically, D-12 emotional 223 
subscale would be expected to correlate more strongly with the HADS than the D-12 physical 224 
subscale, and this assumption was precisely captured in our findings. Similar to our previous findings 225 
[21-23], correlations between D-12 and HADS were only moderate. This suggested the difference of 226 
the focus of emotional distress between D-12 and HADS, with the former capturing the emotional 227 
status related to dyspnoea and the latter focusing more on the general status of emotional problems 228 
[23].  229 
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Breathlessness is a negative predictor of QoL in lung cancer [2, 5, 37], and this was sensitively 230 
captured by the D-12 as significant correlations were shown between D-12 and LCSS. Factor analysis 231 
supported very good construct validity of the D-12, which was highly consistent with the factor 232 
analysis result during the development stage of the D-12 [20].  233 
It is not surprising that no gender and age difference was detected across D-12 scores, as age and 234 
gender have been reported not to be related to dyspnoea in lung cancer [6]. Also, during the D-12 235 
development stage, items with gender or age bias had already been abandoned [20, 22]. Patients 236 
with anxiety or depression experienced more severe dyspnoea than those without such affective 237 
distress, as expected, because emotional problems such as anxiety and depression have been noted to 238 
be closely associated with breathlessness distress in lung cancer [6, 38, 39]. 239 
Breathlessness is one of the leading symptoms in COPD [40, 41]. COPD patients tend to experience 240 
similar or more severe dyspnoea and impaired QoL than that in lung cancer patients at a 241 
comparable advanced disease stage [42-44]. Lung cancer patients with COPD are expected to 242 
experience more severe dyspnoea than those without COPD, and this was accurately captured by 243 
the D-12 as patients with COPD had significantly higher D-12 scores than non-COPD patients. 244 
The study has some limitations. Sample size estimation in the feasibility trial was not powered for 245 
the purpose of estimating psychometric properties. The D-12 scores in the control group subjects 246 
were not appropriate for estimating test-retest reliability because there was not a suitable anchor 247 
from the outcome measures that can be used to ensure patients’ stability over time. D-12 divergent 248 
validity was also not performed due to the absence of available data. Despite these limitations, our 249 
study demonstrated that the D-12 is a valid and reliable assessment for breathlessness in lung 250 
cancer. Given its MCID was also identified [24], the D-12 can be a good option for use in future lung 251 
cancer trials to measure patients’ breathlessness severity. Also, psychometric properties of the D-252 
12 in lung cancer are consistent with previous validation studies in other respiratory diseases 253 
[20-23], which indicates its promising role for measuring breathlessness in a wide range of 254 
conditions. 255 
Conclusion 256 
D-12 is a valid and reliable patient-reported instrument for measuring breathlessness in patients 257 
with lung cancer. Future lung cancer studies are encouraged to adopt the D-12 as one of the outcome 258 
measures for breathlessness assessment. 259 
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TABLES 362 
Table 1 Demographic and clinical characteristics of the study sample (N=101) 363 
Demographic and clinical characteristics Number (%) 
Age (year) 80-99 7 (6.9) 
60-79 80 (79.2) 
40-59 13 (12.9) 
20-39 1 (1.0) 
Mean (SD) 67.7±9.6 
Gender Female 54 (53.5) 
Male 47 (46.5) 
Employment Status Retired 59 (58.4) 
Retired for health reasons 25 (24.8) 
In paid employment 7 (6.9) 
Self-employed 2 (2.0) 
Housewife 2 (2.0) 
Long term sickness 2 (2.0) 
Disabled 2 (2.0) 
Never worked 1 (1.0) 
Not recorded 1 (1.0) 
Patient ever smoked Yes 93 (92.1) 
No 8 (7.9) 
Diagnosis of COPD Yes 39 (38.6) 
No 61 (60.4) 
Not recoded 1 (1.0) 
Symptom cluster Presence of breathlessness 99 (98.0) 
Presence of cough 81 (80.2) 
Presence of fatigue 99 (98.0) 
Emotional status Presence of anxiety (HADS-A ≥8) 32 (31.7) 
Presence of depression (HADS-D ≥8) 39 (38.6) 
Treatment group status Absence of further active antineoplastic therapy  12 (11.9) 
Post-curative treatment 37 (36.6) 
Follow-up palliative cancer care 52 (51.5) 
HADS-A: Hospital Anxiety and Depression Scale-Anxiety; HADS-D: Hospital Anxiety and Depression Scale-364 
Depression  365 
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Table 2 Associations between D-12 and NRS, HADS and LCSS 367 
 D-12 total  D-12 physical D-12 emotional 
NRS scales 
NRS-average breathlessness 0.495a 0.475a 0.481a 
 NRS-worst breathlessness 0.514a 0.512a 0.495a 
 NRS-distress associated with breathlessness 0.611a 0.552a 0.642a 
 NRS-ability to cope with breathlessness -0.165 -0.139 -0.131 
 NRS-unpleasant associated with breathlessness 0.556a 0.556a 0.555a 
HADS 
HADS total 0.585a 0.465a 0.673a 
HADS anxiety 0.628a 0.486a 0.706a 
HADS depression 0.463a 0.390a 0.526a 
LCSS total 0.551a 0.524a 0.525a 
D-12: Dyspnoea-12; NRS: Numerical Rating Scale; HADS: Hospital Anxiety and Depression Scale; LCSS: Lung 368 
Cancer Symptom Scale 369 
a: significant at 0.01 370 
 371 
Table 3 Factor analysis for the D-12 items 372 
D-12 items Factor 1 
(Physical component) 
Factor 2 
(Emotional Component) 
D12-1My breath does not go in all the way 0.684 0.221 
D12-2 My breathing requires more work 0.723 0.345 
D12-3 I feel short of breath 0.740 0.242 
D12-4 I have difficulty catching my breath 0.813 0.313 
D12-5 I cannot get enough air 0.771 0.419 
D12-6 My breathing is uncomfortable 0.759 0.363 
D12-7 My breathing is exhausting 0.697 0.527 
D12-8 My breathing makes me feel depressed 0.317 0.847 
D12-9 My breathing makes me feel miserable 0.302 0.870 
D12-10 My breathing is distressing 0.460 0.775 
D12-11 My breathing makes me agitated 0.336 0.835 
D12-12 My breathing is irritating 0.348 0.787 
D-12: Dyspnoea-12 373 
374 
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Table 4 Discriminate performance of the D-12 for HADS anxiety and depression groups* 375 
D-12 scores Anxious 
(HADS-A ≥ 8) 
Non-anxious 
(HADS-A˂8) 
Depressed 
(HADS-D≥ 8) 
Non-depressed 
(HADS-D˂8) 
 n Mean (SE) n Mean (SE) n Mean (SE) n Mean (SE) 
D-12 total 32 25.0(1.5) 65 13.7 (0.9) 39 23.1 (1.4) 59 13.8(1.0) 
D-12 physical 28 14.3 (1.0) 61 9.3 (0.6) 33 13.7 (0.8) 57 9.3 (0.7) 
D-12 emotional 32 10.7 (0.7)  63 4.3 (0.5) 38 9.7 (0.7) 58 4.4 (0.5) 
All differences were statistically significant at P˂0.001. 376 
D-12: Dyspnoea-12; HADS: Hospital Anxiety and Depression Scale; HADS-A: Hospital Anxiety and Depression 377 
Scale-Anxiety; HADS-D: Hospital Anxiety and Depression Scale-Depression 378 
Note: D-12 total and all subscale score differences between anxious and non-anxious patients, and D-12 total and 379 
emotional score differences between depressed and non-depressed patients were tested by Mann-Whitney U 380 
test, while D-12 physical score difference between depressed and non-depressed patients was analysed by 381 
Independent-samples t-test, based on the normality test results as measured by Shapiro-Wilk approach. 382 
 383 
Table 5 Discriminate performance of the D-12 between patients with and without COPD 384 
D-12 scores COPD patients Non-COPD patients P value 
 n Mean (SE) n Mean (SE)  
D-12 totala 39 20.7 (1.5) 61 15.7 (1.1) 0.012 
D-12 physicalb 36 12.7 (0.9) 54 9.7 (0.7) 0.007 
D-12 emotionala 37 8.0 (0.8) 60 5.6 (0.6) 0.015 
D-12: Dyspnoea-12 385 
a:Mann-Whitney U test; b:Independent-samples t-test386 
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Figure 388 
 389 
Figure 1 Distribution of D-12 total and component scores 390 
D-12: Dyspnoea-12 391 
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